Results 41 to 50 of about 67,160 (259)
The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo +9 more
wiley +1 more source
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Background Immune checkpoint inhibitors (ICIs) can be commonly associated with the occurrence of immune-related adverse drug reactions (irADRs), which can involve any tissue and organ.
Maria Maddalena Nicoletti +8 more
doaj +1 more source
Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet +11 more
wiley +1 more source
End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012
Although the management of scleroderma continues to evolve, it is unknown whether the burden of end-stage kidney disease (ESKD) treated with maintenance renal replacement therapy from SD has changed.
Donal J. Sexton +2 more
doaj +1 more source
Localized scleroderma – current treatment options
Localized scleroderma (morphea) is a connective tissue disease that affects the skin, subcutaneous tissue and underlying tissues including the fasciae, muscles and bones. The treatment of localized scleroderma depends on the clinical form of the disease,
Małgorzata Michalska-Jakubus +2 more
core +1 more source
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? [PDF]
Scleroderma is an autoimmune disease with a characteristic vascular pathology. The vasculopathy associated with scleroderma is one of the major contributors to the clinical manifestations of the disease.We used immunohistochemical and mRNA in situ ...
Jo N Fleming +12 more
doaj +1 more source
Optimization of Scleroderma spore inoculum for Eucalyptus nurseries in China [PDF]
Scleroderma, a genus of ectomycorrhizal (ECM) fungi, is often associated with trees in disturbed habitats and is therefore considered to be suitable for use in plantation forestry.
Chen, Yinglong
core
Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns
Objective The aim of this study was to characterize specific physiologic defects in anorectal dysfunction in systemic sclerosis (SSc) using anorectal manometry (ARM), evaluate associations with gastrointestinal (GI) and extraintestinal clinical phenotypes, and explore potential serologic markers for risk stratification.
Timothy Kaniecki +6 more
wiley +1 more source
Background Patient engagement in research is important to ensure research questions address problems important to patients, that research is designed in a way that can effectively answer those questions, and that findings are applicable, relevant, and ...
Amanda Wurz +14 more
doaj +1 more source

